Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

By Higano C.S.   Ellis W.   Russell K.   Lange P.H.  

Urology, Vol. 48, Iss. 5, 1996-11 ,pp. : 800-804

Elsevier

Access to resources Recommend Favorite

Combined androgen blockade for the treatment of metastatic cancer of the prostate

By Schellhammer P.F.  

Urology, Vol. 47, Iss. 5, 1996-05 ,pp. : 622-628

Elsevier

Access to resources Recommend Favorite

Pilot attempt of advanced prostate cancer treatment T3NxMx−1 by intermittent more complete androgen blockade

By Dutkiewicz Slawomir  

International Urology and Nephrology, Vol. 36, Iss. 3, 2004-09 ,pp. : 359-363

Springer Publishing Company

Access to resources Recommend Favorite

The prognostic importance of prostate specific antigen in the monitorisation of patients undergoing maximum androgen blockade for metastatic prostate cancer

By Kiper Ahmet   Yiğitbası Orhan   Imamoglu Abdurrahim   Tuygun Can   Turan Celaleddin  

International Urology and Nephrology, Vol. 38, Iss. 3-4, 2006-12 ,pp. : 571-576

Springer Publishing Company

Access to resources Recommend Favorite

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate

By Brufsky A.   Fontaine-Rothe P.   Berlane K.   Rieker P.   Jiroutek M.   Kaplan I.   Kaufman D.   Kantoff P.  

Urology, Vol. 49, Iss. 6, 1997-06 ,pp. : 913-920

Elsevier

Access to resources Recommend Favorite